Biocon’s APIs Manufacturing Facility in Telangana Completes U.S. FDA Inspection with No 483 Observations

Bengaluru, India, December 17, 2018

“The U.S. FDA conducted a GMP inspection of our APIs manufacturing facility at Telangana from Dec 12- Dec 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects our strong commitment to quality and cGMP compliance.”

– Company Spokesperson